Immunostimulant In Situ Hydrogel Improves Synergetic Radioimmunotherapy of Malignant Glioblastoma Relapse Post‐Resection (Adv. Funct. Mater. 43/2022)

Immunostimulant In Situ Hydrogel Improves Synergetic Radioimmunotherapy of Malignant Glioblastoma Relapse Post‐Resection (Adv. Funct. Mater. 43/2022)

Flexible Optoelectronics In article number 2205038, Huae Xu, Hongyi Liu, Jing Ji, Yun Chen, and co‐workers present an injectable, reactive oxygen species‐responsive therapeutic hydrogel (ADU‐AAV‐PD1@Gel), capable of sustained local release of soluble PD‐1 (sPD‐1) and STING agonist ADU‐S100. The ADU‐...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced functional materials 2022-10, Vol.32 (43), p.n/a
Hauptverfasser: Sun, Shuo, Gu, Wei, Wu, Haisi, Zhao, Qianqian, Qian, Shiyu, Xiao, Hong, Yang, Kun, Liu, Jian, Jin, Yu, Hu, Chupeng, Gao, Ye, Xu, Huae, Liu, Hongyi, Ji, Jing, Chen, Yun
Format: Artikel
Sprache:eng
Schlagworte:
glioblastoma
hydrogels
PD‐1
radioimmunotherapy
STING pathway
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Flexible Optoelectronics In article number 2205038, Huae Xu, Hongyi Liu, Jing Ji, Yun Chen, and co‐workers present an injectable, reactive oxygen species‐responsive therapeutic hydrogel (ADU‐AAV‐PD1@Gel), capable of sustained local release of soluble PD‐1 (sPD‐1) and STING agonist ADU‐S100. The ADU‐AAV‐PD1@Gel combined with radiotherapy generates a robust antitumor immune response and induces long‐term immune memory to prevent glioblastoma recurrence.
ISSN:1616-301X
1616-3028
DOI:10.1002/adfm.202270246